KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2026)

Aquestive Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $1.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 42.74% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $7.6 million, up 7.4%, while the annual FY2025 figure was $7.6 million, 7.4% up from the prior year.
  • Share-based Compensation for Q4 2025 was $1.4 million at Aquestive Therapeutics, down from $2.8 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $2.8 million in Q3 2025 and troughed at $344000.0 in Q1 2023.
  • A 5-year average of $1.4 million and a median of $1.6 million in 2024 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: crashed 71.84% in 2022 and later surged 359.3% in 2024.
  • Year by year, Share-based Compensation stood at $1.7 million in 2021, then plummeted by 57.78% to $714000.0 in 2022, then surged by 31.65% to $940000.0 in 2023, then surged by 155.64% to $2.4 million in 2024, then crashed by 42.74% to $1.4 million in 2025.
  • Business Quant data shows Share-based Compensation for AQST at $1.4 million in Q4 2025, $2.8 million in Q3 2025, and $1.9 million in Q2 2025.